A icon

Agilent Technologies

147.36 USD
+2.64
1.82%
At close Jan 17, 4:00 PM EST
After hours
147.36
+0.00
0.00%
1 day
1.82%
5 days
7.39%
1 month
7.99%
3 months
7.23%
6 months
10.38%
Year to date
10.44%
1 year
15.02%
5 years
63.52%
10 years
288.51%
 

About: Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.

Employees: 17,900

0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

59% more first-time investments, than exits

New positions opened: 132 | Existing positions closed: 83

9% more capital invested

Capital invested by funds: $33.9B [Q2] → $37B (+$3.07B) [Q3]

4% more funds holding

Funds holding: 994 [Q2] → 1,030 (+36) [Q3]

10% less repeat investments, than reductions

Existing positions increased: 339 | Existing positions reduced: 375

4.08% less ownership

Funds ownership: 89.72% [Q2] → 85.64% (-4.08%) [Q3]

8% less funds holding in top 10

Funds holding in top 10: 13 [Q2] → 12 (-1) [Q3]

24% less call options, than puts

Call options by funds: $122M | Put options by funds: $162M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$135
8%
downside
Avg. target
$147
0%
upside
High target
$160
9%
upside

5 analyst ratings

positive
40%
neutral
40%
negative
20%
B of A Securities
Derik De Bruin
68% 1-year accuracy
13 / 19 met price target
2%upside
$150
Neutral
Maintained
13 Dec 2024
Wells Fargo
Brandon Couillard
44% 1-year accuracy
8 / 18 met price target
5%upside
$155
Overweight
Maintained
9 Dec 2024
Barclays
Luke Sergott
23% 1-year accuracy
11 / 48 met price target
8%downside
$135
Underweight
Maintained
27 Nov 2024
Bernstein
Eve Burstein
57% 1-year accuracy
4 / 7 met price target
8%downside
$135
Market Perform
Maintained
26 Nov 2024
JP Morgan
Rachel Vatnsdal
47% 1-year accuracy
8 / 17 met price target
9%upside
$160
Overweight
Maintained
26 Nov 2024

Financial journalist opinion

Based on 5 articles about A published over the past 30 days

Negative
Zacks Investment Research
4 days ago
Agilent Rises 11% in a Year: Should You Buy, Sell or Hold the Stock?
A faces challenges with slowing end-market demand and regulatory hurdles in China, raising growth concerns.
Agilent Rises 11% in a Year: Should You Buy, Sell or Hold the Stock?
Neutral
Seeking Alpha
5 days ago
Agilent Technologies, Inc. (A) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
Agilent Technologies, Inc. (NYSE:A ) J.P. Morgan 43rd Annual Healthcare Conference January 14, 2025 12:45 PM ET Company Participants Padraig McDonnell - President and CEO Robert McMahon - Senior VP and CFO Conference Call Participants Rachel Vatnsdal - JPMorgan Rachel Vatnsdal Good morning, everyone.
Agilent Technologies, Inc. (A) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
Neutral
Business Wire
1 week ago
Agilent Presents Solutions Innovation Research Awards to Aarhus University, University of Graz, and Imperial College London Scientists
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced Solutions Innovation Research Awards (SIRA) have been presented to Professor Anders Bentien of Aarhus University, Professor Walter Gössler of University of Graz, and Professor Gregory Offer of Imperial College London. These separate awards recognize their outstanding contributions to battery research. Developing new materials for more efficient and durable batteries is essential to reducing fossil fuel rel.
Agilent Presents Solutions Innovation Research Awards to Aarhus University, University of Graz, and Imperial College London Scientists
Positive
Zacks Investment Research
3 weeks ago
Agilent (A) Up 1.3% Since Last Earnings Report: Can It Continue?
Agilent (A) reported earnings 30 days ago. What's next for the stock?
Agilent (A) Up 1.3% Since Last Earnings Report: Can It Continue?
Neutral
Zacks Investment Research
4 weeks ago
Is the Options Market Predicting a Spike in Agilent (A) Stock?
Investors need to pay close attention to Agilent (A) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Agilent (A) Stock?
Neutral
Business Wire
1 month ago
Agilent to Present at the 43rd Annual J.P. Morgan Healthcare Conference
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Bob McMahon will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 14, 2025, at 9:45 a.m. Pacific time. A live audio webcast and replay of the presentation will be available on the Agilent Investor Relations website. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical lab.
Agilent to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Positive
CNBC Television
1 month ago
Agilent CEO Padraig McDonnell sees 'long runway' in advancing therapeutics
Padraig McDonnell, Agilent CEO, joins 'Closing Bell Overtime' to talk investors day, its healthcare segment, and more.
Agilent CEO Padraig McDonnell sees 'long runway' in advancing therapeutics
Neutral
Business Wire
1 month ago
Agilent Companion Diagnostic Assay PD-L1 IHC 28-8 pharmDx Receives European IVDR Certification
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the issuing of a Class C companion diagnostic In Vitro Diagnostic Regulation (IVDR) certification for PD-L1 IHC 28-8 pharmDx (Code SK005). This CDx assay has previously been CE-IVD–marked for sales in the European Union and is now certified in accordance with the new EU Regulation for in vitro diagnostic medical devices (IVDR) 1. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the Agilent Autosta.
Agilent Companion Diagnostic Assay PD-L1 IHC 28-8 pharmDx Receives European IVDR Certification
Positive
Zacks Investment Research
1 month ago
Agilent Gains 5% in a Month: Should You Buy, Sell or Hold the Stock?
A's shares ride on the bright performance of the Agilent CrossLab Group segment and strategic acquisitions.
Agilent Gains 5% in a Month: Should You Buy, Sell or Hold the Stock?
Neutral
Zacks Investment Research
1 month ago
International Markets and Agilent (A): A Deep Dive for Investors
Examine Agilent's (A) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
International Markets and Agilent (A): A Deep Dive for Investors
Charts implemented using Lightweight Charts™